The American Journal of Medicine
Volume 120, Issue 8, Supplement 1 , Pages S1-S3 , August 2007

Introduction

  • Robert A. Wise, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationRequests for reprints should be addressed to Robert A. Wise, MD, Johns Hopkins University School of Medicine, Division of Pulmonary and Critical Care Medicine at the JHU Asthma and Allergy Center, 5501 Hopkins Bay View Circle, Room 4B.74, Baltimore, MD 21224.
    • ,
  • Donald P. Tashkin, MD

      Affiliations

    • Division of Pulmonary, Critical Care Medicine, and Hospitalists, David Geffen School of Medicine at UCLA, University of California–Los Angeles, Los Angeles, California

References 

  1. National Heart, Lung, and Blood Institute, National Institutes of Health. Chronic obstructive pulmonary disease data fact sheet. Available at: http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.htm. Accessed June 23, 2006.
  2. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294:1255–1259
  3. Voelkel NF. Raising awareness of COPD in primary care. Chest. 2000;117(suppl 2):372S–375S
  4. Celli BR, MacNee W, Agusti A, et al. ATS/ERS Task Force Committee Members Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  5. National Heart, Lung, and Blood InstituteNational Institutes of Health. Chronic Obstructive Lung Disease: Summary of the Health Consequences of Smoking. A Report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1984;
  6. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary). Am J Respir Crit Care Med. 2001;163:1256–1276
  7. American Thoracic SocietyEuropean Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900
  8. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Workshop Report. National Heart, Lung, and Blood Institute, National Institutes of Health, US Dept of Health and Human Services; 2006;Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=1151. Accessed April 4
  9. Fletcher C, Peto R. The natural history of chronic airflow obstruction. [review] BMJ. 1977;1:1645–1648
  10. Anthonisen NR, Connett JE, Murray RP Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675–679
  11. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–239
  12. Rennard SI, Daughton DM. Smoking cessation. Chest. 2000;117(suppl):360S–364S
  13. Zhu S-H, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med. 2002;347:1087–1093
  14. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202
  15. Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63
  16. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691
  17. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357:1571–1575
  18. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(suppl):121S–126S
  19. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2006. Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed April 26, 2007.
  20. Petty TL. Benefits of and barriers to the widespread use of spirometry. Curr Opin Pulm Med. 2005;11:115–120
  21. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. MMWR Surveill Summ. 2002;51:1–16
  22. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  23. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2:CD004403
  24. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006;4:101–124
  25. Niewoehner DE, Erbland ML, Deupree RH, et al. Department of Veterans Affairs Cooperative Study Group Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1941–1947
  26. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456–460
  27. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618–2625
  28. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000;355:362–368
  29. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391–398
  30. Fishman A, Martinez F, Naunheim K, et al. National Emphysema Treatment Trial Research Group A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–2073

PII: S0002-9343(07)00402-0

doi: 10.1016/j.amjmed.2007.04.006

The American Journal of Medicine
Volume 120, Issue 8, Supplement 1 , Pages S1-S3 , August 2007

Article Tools